Starpharma granted fast track approval for VivaGel

Company News

by Jessica Amir

Starpharma Holdings Limited, (ASX:SPL) says the FDA has granted a fast track designation as well as a Qualified Infectious Disease Product designation, for its VivaGel product.

VivaGel is used for the treatment and prevention of bacterial vaginoisis in women.

Starpharma has estimated that the market relating to the treatment and prevention of this infection is worth in excess of US$1 billion.

The company says it’s a very positive commercial development which expedites the path to US market entry for VivaGel.

Starpharma posted a net loss of $22.7 million at 30 June 2016.
 

Jessica Amir

Finance News Network
Jessica is a senior finance journalist and presents bulletins including the Market Outlook, Market at Midday and Market Wrap. She also interviews ASX CEOs and leading fund managers. She joined FNN in January 2017 with over six years of broadcast journalism experience including with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for Prime 7 and WIN News. Jessica has worked in financial planning for over six years with leading wealth managers and in real estate.